Evidence map›Paper›PMID 33177851›Full record

ArticleClinicoEconomics and outcomes research : CEOR2020

Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis.

Vladimir Zah, Jovana Pelivanovic, Simona Tatovic, Djurdja Vukicevic, Martina Imro, Jane Ruby, David Hurley

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Vladimir ZahHealth Economics and Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON, Canada.ORCID 0000-0003-1368-4491
Jovana PelivanovicHealth Economics and Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON, Canada.
Simona TatovicHealth Economics and Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON, Canada.
Djurdja VukicevicHealth Economics and Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON, Canada.ORCID 0000-0001-9591-1111
Martina ImroHealth Economics and Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON, Canada.ORCID 0000-0003-0440-9375
Jane RubyMedical Affairs, Endo Pharmaceuticals Inc., Malvern, PA, USA.
David HurleyMedical Affairs, Endo Pharmaceuticals Inc., Malvern, PA, USA.ORCID 0000-0001-9946-7572
Endo Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveStudies examining differences in US healthcare resource utilization (HCRU) and associated healthcare costs between collagenase clostridium histolyticum (CCH) and fasciectomy for Dupuytren contracture (DC) are limited. This study evaluated US HCRU and direct healthcare cost for the treatment of DC in privately insured patients using insurance claims.

methodsThis retrospective observational cohort study analyzed data from large nationwide insurance claims databases; it included individuals diagnosed with DC between July 1, 2011, and June 30, 2017, who were adults at index date (date of first treatment: CCH or fasciectomy). Participants had continuous health plan coverage 24 months pre-index and 12 months post-index date. All-cause and DC-related HCRU and healthcare costs from the payers' perspective were compared between propensity score-matched cohorts. Generalized linear models assessed factors associated with all-cause total healthcare costs.

resultsOf 83,983 patients diagnosed with DC, 1932 adults receiving fasciectomy and 953 adults receiving CCH were included. The mean ± standard deviation total all-cause healthcare cost was significantly lower with CCH than with fasciectomy (US$11,897 ± US$14,633 versus US$15,528 ± US$22,254, respectively;

conclusionBased on matched cohort data, adjusted 1-year healthcare costs for CCH-treated individuals were significantly lower compared with costs for fasciectomy-treated individuals.

Indexed as

injectioninsurance claimsretrospective database studysurgery

Identifiers

PMID33177851
PMCPMC7649243
OpenAlexW3097419277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.